Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-12-19

FDA Approved: SEGLUROMET — Original Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

FDA approved Segluromet (ertugliflozin and metformin hydrochloride) under an original application by Merck Sharp & Dohme LLC for the treatment of type 2 diabete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SEGLUROMET (ertugliflozin and metformin hydrochloride)

Snippet

ORIG AP for SEGLUROMET (ERTUGLIFLOZIN AND METFORMIN HYDROCHLORIDE)